Jci_page_head_homepage_01 Jci_page_head_homepage_02
Christopher S. Rogers, Yanhong Hao, Tatiana Rokhlina, Melissa Samuel, David A. Stoltz, Yuhong Li, Elena Petroff, Daniel W. Vermeer, Amanda C. Kabel, Ziying Yan, Lee Spate, David Wax, Clifton N. Murphy, August Rieke, Kristin Whitworth, Michael L. Linville, Scott W. Korte, John F. Engelhardt, Michael J. Welsh, Randall S. Prather
Published in Volume 118, Issue 4
J Clin Invest. 2008; 118(4):1571–1577 doi:10.1172/JCI34773
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 2
Schematic of targeting constructs for homologous recombination for CFTR-null and CFTR-ΔF508.

Exons 8–11 of pig CFTR are depicted as black boxes. NeoR contains a neomycin resistance cDNA (orange) driven by the phosphoglycerate kinase (PGK) promoter (yellow) and flanked by loxP sites (blue). The engineered stop codon is indicated in the CFTR-null targeting vector. The inverted terminal repeats (ITRs) are at both ends of the targeting construct. Position of probes for NeoR and CFTR Southern blots are indicated. PCR screen primers are depicted as arrowheads. BglII sites are indicated. Not drawn to scale.